Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD

Baruch D. Kuppermann, MD, PhD

Video
Published 2020

Related

Episode 12: RPE Stem Cells for Dry AMD with Dr. Mark Humayun
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Common Age-Related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Chroma and Spectri Phase 3 Lampalizumab Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2018
Machine and Deep Learning (AI) Algorithms for GA Identification and Prediction of Progression to GA from Intermediate AMD: The Future of Dry AMD Management
Eleonora Lad, MD, PhD
Updates from the Field
2023

Category: AMD-Neovascular

See more